Allergan's Tazorac Receives U.S. FDA Approval for a New Cream Formulation.

Business Editors & Health/Medical Writers

IRVINE, Calif.--(BW HealthWire)--Oct. 2, 2000

Allergan, Inc. (NYSE:AGN) today announced it has received approval from the United States Food & Drug Administration (FDA) to market Tazorac(R) (tazarotene) Cream 0.05% and 0.1% for the treatment of plaque psoriasis.

Tazorac(R) Cream is a new formulation of topical, receptor-selective retinoid specifically designed to deliver effective retinoid action with a low occurrence of burning and irritation. Since 1997, Tazorac(R) (tazarotene) Gel 0.05% and 0.1% have been FDA approved for the treatment of stable plaque psoriasis and Tazorac(R) Gel 0.1% has been indicated for mild to moderate facial acne vulgaris.

"The cream formulation of Tazorac(R) is a complement to Tazorac(R) gel, one of our fastest growing products," said Mike Ball, corporate vice president and president, North America Region. "Expanding upon our Tazorac(R) product line provides physicians an effective new prescription option for treating a broad range of patients with varied skin types, including those with dry or sensitive skin."

Tazorac(R) gel has been one of Allergan's fastest growing products with worldwide net product sales of $14.4 million for the six months ended June 30, 2000, up 67.4% over last year.

About Allergan, Inc.

Allergan, Inc., headquartered in Irvine, California, is a technology-driven global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.

Forward-Looking Statements

This press release contains "forward-looking statements", such as statements regarding the effectiveness of the Tazorac(R) gel and cream formulations, potential growth rates and availability of these products. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry and pharmaceutical market conditions; general domestic and international economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product marketing such as the unpredictability of market acceptance for a new pharmaceutical product; potential difficulties in manufacturing a new product formulation; domestic and foreign health care reforms; and trends toward managed care and health care cost containment, and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Allergan and Its Businesses" in Allergan's 1999 Annual Report on Form 10-K and Form 10-Q for the quarter ended June 30, 2000. Allergan's filings are available publicly and upon request from Allergan's Investor Relations Department: 714.246.4636 or http://www.allergan.com.